CSF1R and neoplasm: At 72 h after [89Zr]Zr-DFO-N-suc-IgG2a administration, there was a higher presence in tumor and blood pool and less in the liver and spleen than for [89Zr]Zr-DFO-N-suc-CSF1R-mAb (Figures 5B–E).